Abeona Activates NewYork-Presbyterian/Columbia as Fifth ZEVASKYN Treatment Center
Abeona Therapeutics has activated NewYork-Presbyterian/Columbia University Irving Medical Center as the fifth Qualified Treatment Center for ZEVASKYN, expanding patient access in the New York metro and Northeast. ZEVASKYN, the first autologous gene-modified cell therapy for RDEB wounds, has delivered clinically meaningful healing and pain relief in adult and pediatric patients.
1. Activation of Fifth Qualified Treatment Center
Abeona has officially added NewYork-Presbyterian/Columbia University Irving Medical Center to its network, marking the fifth Qualified Treatment Center for ZEVASKYN. This expansion enhances patient access across the New York metropolitan area and throughout the Northeast, leveraging Columbia’s expertise in genetic medicine and long-standing care model for blistering skin disorders.
2. ZEVASKYN Therapy Profile and Patient Support
ZEVASKYN is the first and only autologous cell sheet-based gene therapy indicated for adult and pediatric RDEB wounds, offering a single surgical application that promotes durable wound closure and pain reduction. Abeona Assist provides comprehensive support including insurance navigation, financial assistance, travel logistics, and lifelong monitoring guidance to optimize patient outcomes.